Ularitide (Urodilatin)
Overview
Ularitide is a synthetic 32-amino acid peptide analogue of urodilatin, a natriuretic peptide produced in renal tubular cells. It binds to guanylyl cyclase A receptors to increase cyclic GMP, resulting in vasodilation, enhanced sodium excretion, and suppression of the renin-angiotensin-aldosterone system. The peptide was developed for treatment of acute decompensated heart failure with the goal of improving renal function and hemodynamics.
Key Research Findings
The TRUE-AHF trial (European Heart Journal, 2017) evaluated ularitide in over 2,000 patients with acute heart failure but did not meet its primary endpoint of cardiovascular mortality reduction. Despite promising earlier phase 2 data showing hemodynamic benefits, regulatory approval was not pursued following the neutral phase 3 results.
Intravenous
In Clinical Trials
Interested in Ularitide (Urodilatin)?
Find a verified provider experienced with Ularitide (Urodilatin) protocols in your area. All providers are credentialed and use compliant sourcing.
Find a Ularitide (Urodilatin) ProviderRelated Peptides
Eptifibatide (Integrilin)
FDA ApprovedA synthetic cyclic heptapeptide modeled after the KGD (Lys-Gly-Asp) disintegrin sequence found in the venom of the southeastern pygmy rattlesnake (Sistrurus miliarius barbouri). Eptifibatide is a potent, reversible glycoprotein IIb/IIIa receptor antagonist that blocks the final common pathway of platelet aggregation by preventing fibrinogen and von Willebrand factor binding to activated platelets.
Nesiritide (Natrecor)
FDA ApprovedA recombinant form of human B-type natriuretic peptide (BNP), a 32-amino acid peptide naturally produced by ventricular cardiomyocytes in response to volume overload and wall stress. Nesiritide binds natriuretic peptide receptor A (NPR-A), activating guanylyl cyclase and increasing intracellular cGMP to produce venous, arterial, and coronary vasodilation, natriuresis, and suppression of the renin-angiotensin-aldosterone and sympathetic nervous systems.
Angiotensin II (Giapreza)
FDA ApprovedA synthetic form of the endogenous octapeptide angiotensin II, the primary effector of the renin-angiotensin system. Angiotensin II acts on AT1 receptors on vascular smooth muscle to produce potent vasoconstriction, and on the adrenal cortex to stimulate aldosterone release. Exogenous administration raises blood pressure in vasodilatory shock refractory to conventional vasopressors by restoring vascular tone through a mechanism complementary to catecholamine vasopressors.
Serelaxin (Relaxin-2)
InvestigationalSerelaxin is a recombinant form of human relaxin-2, a naturally occurring peptide hormone composed of two chains linked by disulfide bonds. It acts via the relaxin family peptide receptor 1 (RXFP1) to promote vasodilation, inhibit fibrosis, and modulate hemodynamics. The therapeutic rationale targets acute heart failure by improving renal perfusion and reducing vascular resistance.